Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 06

403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups


03 Dec 2022


Poster viewing 06


Global Cancer Statistics;  Career Development

Tumour Site


Thi Thao Vi Luong


Annals of Oncology (2022) 33 (suppl_9): S1598-S1618. 10.1016/annonc/annonc1135


T.T.V. Luong1, C.H. Ho2, V. Aedo-Lopez1, E. Segelov3

Author affiliations

  • 1 Oncology, Monash Health - Monash Cancer Centre, 3168 - Melbourne/AU
  • 2 Medicine, Monash University, 3800 - Clayton/AU
  • 3 Oncology Dept, Monash Health - Monash Medical Centre, 3168 - Clayton/AU

Abstract 403P


Despite increased global effort in promoting gender equity in medicine, progress remains slow, particularly with respect to clinical research and leadership roles. Our study assesses trends in female Principal Investigators (PI) amongst academic Cancer Clinical Trials Groups in Australia.


The publicly accessible areas of 14 Australian cancer clinical trial group websites were reviewed for trial details, including year of registration, details of PI, and the presence of any gender policies or statements. Data was collected on xxx date. Data was available for: the Australasian Gastrointestinal Trials Group (AGITG), Thoracic Oncology Group Australia (TOGA), Breast Cancer Trials (BCT), Australia and New Zealand Gynaecological Oncology Group (ANZGOG), Australia and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Melanoma And Skin Cancer Trials (MASC), Cooperative Trials Group for Neuro-Oncology (COGNO), The Trans Tasman Radiation Oncology Group (TROG), Australia and New Zealand Sarcoma Association (ANZSA), Palliative Care Clinical Studies Collaborative (PaCCSC), Cancer Research in Primary Care (PC4). Three groups did not post PI details: The Psycho-Oncology Co-operative Research Group (PoCoG), The Australian and New Zealand Children’s Haematology-Oncology Group (ANZCHOG), The Australasian Leukaemia and Lymphoma Group (ALLG).


Eleven trial groups reported 355 studies, registered between 1994 and 2022. There were 410 trial PIs, of which 152 (37%) were female. There were no female PIs in any group prior to 2003. Despite a rise of female PIs after this time with an average of 0.5 PI per 10-years, women remain under-represented. For trials with a sole PI (n=276), 110 were led by women (39%). For trials with multiple PIs (n=58), 25 included women (43%). Despite having the lowest female PI presence, ANZUP was the only trial group with a gender equity statement.


Despite a slow steady rise of female PI between 1994 and 2022, women have not achieved equity as PI within Australian cancer clinical trials groups. Most groups do not have a publicly available gender policy. Groups without information about PI gender should be encouraged to make this publicly available.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.